Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AtriCure Inc | ATRC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
43.91 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 32.51 - 59.61 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 43.91 | USD |
AtriCure Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.08B | 47.35M | - | 330.38M | -46.47M | -0.98 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AtriCure News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATRC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 41.71 | 44.23 | 40.47 | 42.50 | 349,663 | 2.20 | 5.27% |
1 Month | 45.53 | 46.2228 | 40.47 | 43.26 | 317,581 | -1.62 | -3.56% |
3 Months | 48.55 | 59.61 | 40.47 | 49.23 | 328,833 | -4.64 | -9.56% |
6 Months | 40.94 | 59.61 | 39.025 | 47.69 | 298,051 | 2.97 | 7.25% |
1 Year | 39.00 | 59.61 | 32.51 | 44.38 | 307,388 | 4.91 | 12.59% |
3 Years | 40.54 | 89.18 | 32.51 | 54.51 | 304,093 | 3.37 | 8.31% |
5 Years | 36.49 | 89.18 | 22.57 | 46.94 | 299,590 | 7.42 | 20.33% |
AtriCure Description
AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |